Disposition of patients with type 1 or type 2 diabetes
| Type 1 diabetes | Type 2 diabetes | |||
| SC insulin | EXU | SC insulin | EXU | |
| Screened | 42 | 48 | ||
| Assigned to treatment | ||||
| Treated | 24 | 21 | 26 | 24 |
| Completed | 21 | 20 | 24 | 24 |
| Discontinued | 3 | 1# | 2 | 0 |
| Analysed for BAL (primary analysis set) | 20 | 20 | 24 | 24 |
| Analysed for safety (adverse events) | 24 | 21 | 26 | 24 |
| Discontinuations | ||||
| Not related to study drug | 3 | 1 | 2 | 0 |
| Other | 2 | 0 | 1 | 0 |
| Subject defaulted | 1 | 1 | 1 | 0 |
| Total | 3 | 1 | 2 | 0 |
| Study visit completion | ||||
| Baseline (week 0) | 23 | 25 | ||
| SC insulin treatment (week 12) | 22 | 24 | ||
| EXU insulin treatment (week 25) | 21 | 24 | ||
Data are presented as n. SC: subcutaneous; EXU: Exubera®; BAL: bronchoalveolar lavage. #: patient completed the week 25 visit and was lost to follow-up in the 2-week run-out phase.